The role of chemokines in the establishment of HIV latency

Information

  • Research Project
  • 8500507
  • ApplicationId
    8500507
  • Core Project Number
    R56AI095073
  • Full Project Number
    1R56AI095073-01A1
  • Serial Number
    095073
  • FOA Number
    PA-09-152
  • Sub Project Id
  • Project Start Date
    8/1/2012 - 12 years ago
  • Project End Date
    7/31/2013 - 11 years ago
  • Program Officer Name
    LAWRENCE, DIANE M
  • Budget Start Date
    8/1/2012 - 12 years ago
  • Budget End Date
    7/31/2013 - 11 years ago
  • Fiscal Year
    2012
  • Support Year
    01
  • Suffix
    A1
  • Award Notice Date
    7/25/2012 - 12 years ago
Organizations

The role of chemokines in the establishment of HIV latency

DESCRIPTION (provided by applicant): The use of combination antiretroviral therapy (ART) for the treatment of HIV has resulted in a significant reduction in morbidity and mortality, however HIV infection cannot be eradicated with ART alone. The major barrier to eradication of HIV is persistent long lived latently infected resting CD4+ T-cells. Developing strategies to block the establishment of latent infection could be used in addition to ART to eliminate or accelerate the decay of latently infected CD4+ T-cells. Our overall hypothesis is that specific chemokines, molecules involved in controlling T cell migration and recirculation, are critical for facilitating latent infection in resting CD4+ T-cells. Our overall aim is to identify novel interventions to blok infection of resting CD4+ T-cells by targeting host and not viral factors. To address this, we will use a robust model we have recently developed to establish latency in vitro. In this model, resting CD4+ T-cells are incubated with chemokines that bind to chemokine receptors highly expressed on resting cells. After incubation with the relevant chemokines, cells are infected with HIV and high levels of integration and no virus production is observed, consistent with latent infection. Using this model of chemokine-induced latency, we will first determine whether the establishment of latency can be inhibited by either chemokine receptor or chemokine antagonists. Chemokine antagonists are chemokines with progressive truncation of the N-terminus end which acquire antagonist rather than agonist activity. We will specifically target chemokine receptors that we have shown are critical for HIV infection of resting CD4+ T-cells. These include CXCR3, CCR6 and CCR7. The chemokine receptor and chemokine antagonists will be evaluated alone and in combination in vitro. We will then define the mechanisms of how chemokines mediate efficient nuclear localization and integration in resting CD4+ T-cells. We will first identify the critical cytoskeletal pathways required for migration of the virus to the nucleus in a resting CD4+ T-cell. Using fluorescent microscopy we will identify whether the key pathways involve the actin or microtubule cytoskeleton. We will identify whether changes in the cytoskeleton facilitate nuclear localization in resting CD4+ T-cells and whether this is activated by a specific signaling event or simply by T-cell migration alone. Finally, we will explore the rol of the phophoinosito-3-kinase (PI3K) pathway in mediating efficient HIV integration in resting CD4+ T-cells. We will determine the relevant downstream proteins and specific nuclear factors that are important for facilitating integration. We will also define the sites of HIV integration i this model of latency and determine the relationship between integration and transcription factor binding sites. Overall, these studies may ultimately identify novel antiviral targets, specific for blocking latent infection of resting CD4+ T-cells.

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R56
  • Administering IC
    AI
  • Application Type
    1
  • Direct Cost Amount
    251030
  • Indirect Cost Amount
    20082
  • Total Cost
    271112
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    855
  • Ed Inst. Type
  • Funding ICs
    NIAID:271112\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    AMCB
  • Study Section Name
    AIDS Molecular and Cellular Biology Study Section
  • Organization Name
    MONASH UNIVERSITY
  • Organization Department
  • Organization DUNS
    753252691
  • Organization City
    MELBOURNE
  • Organization State
  • Organization Country
    AUSTRALIA
  • Organization Zip Code
    3800
  • Organization District
    AUSTRALIA